NRC FORM 591M PART 1 U.S. NUCLEAR REGULATORY COMMISSION (1-2012)								
10 CFR 2.201 SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATI	ON INSPECTED:	2. NRC/REGIONAL OFFICE						
Genesys Hurley Cancer Institute 302 Kensington Avenue Flint, MI 48503			Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210					
	2012 001	Lisle, IL 60532-4352						
REPORT NUMBER 3. DOCKET NUMBER((S) 5. DATE(S) OF INSPECTION						
030-36106		4. LICENSE NUMBE 21-32322-01	Jel 14, 2012		*			
LICENSEE: The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows: 1. Based on the inspection findings, no violations were identified.								
2. Previous	· · · · · · · · · · · · · · · · · · ·							
The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.								
`	Non-cited violation(s) were discussed involving the following requirement(s):							
					•			
·			•					
	•							
				* .				
. `				•				
4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)								
				•				
			•					
	•							
	•		4	•				
	•							
Chatamant of Commandian Antique								
Statement of Corrective Actions I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.								
TITLE	PRINTED NAME		SIGNATURE		DATE			
LICENSEE'S REPRESENTATIVE								
NRC INSPECTOR	Deborah A. Piskura		OARdans		2/1/2610			
BRANCH CHIEF	Tamara E. Bloomer		19 LDan -		2/23/			

NRC FORM 591M PART 1 (1-2012)

NRC FORM 591M PART 3 U.S. NUCLEAR REGULATORY COMMISSION 10 GFR 2.201 U.S. NUCLEAR REGULATORY COMMISSION 10 GFR 2.201								
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATION INSPE	CTED:		2. NRC/REGIONAL (DEFICE				
Genesys Hurley Cancer 302 Kensington Avenue Flint, MI 48503			Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352					
REPORT NUMBER(S) 2012		,						
3. DOCKET NUMBER(S)		4. LICENSE NUMBER(S	5)	5. DATE(S) OF INSPECTION				
030-36106		21-32322-01	Feb. 14, 2012					
6. INSPECTION PROCEDURES USED		7. INSPECTION FOCUS	7, INSPECTION FOCUS AREAS					
87131 and 87132		03.01-07						
SUPPLEMENTAL INSPECTION INFORMATION								
1. PROGRAM CODE(S) 02230	2. PRIORITY	3. LICENSEE CONTAC		4. TELEPHONE NUMBER				
02230	<u> </u>	Anmed Aki, W.L	Ahmed Akl, M.D., RSO (810) 762-8490					
✓ Main Office Insp	ection	Next Inspection	Date:	Feb. 2014				
Field Office Inspection								
Temporary Job Site Inspection								
PROGRAM SCOPE								
This licensee is a free-standing cancer treatment center with authorization to use materials in Section 35.300 and Ir-192 in an HDR unit. The radiation oncology department was staffed with 3 AMPs, and 2authorized physician users. The licensee administered 5-6 thyroid carcinoma treatments annually; occasionally (1 case in a year) the licensee administered a Zevalin treatment. The licensee administered approximately 25-30 patient treatments annually utilizing its HDR. These treatments included a variety of cancer cases. All HDR patient treatments were administered by the attending radiation oncologist and the authorized medical physicist. Service, maintenance, and source exchanges were performed by the HDR device manufacturer. This inspection consisted of interviews with select licensee personnel; a review of select records; a tour of the radiation oncology department; and independent measurements. The inspector observed the licensee staff administer a patient treatment utilizing its HDR unit. The inspector reviewed the patient's written directive and the treatment plan and interviewed the attending physician and AMP. The inspection included observations of HDR QA and safety checks, security of byproduct material, use of personnel monitoring, and patient surveys.								